Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (06.03.2026)
HOCH Abgang Schlüsselpersonen (06.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 06.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 18.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Unternehmen & Branche
| Name | Drugs Made In America Acquisition II Corp. |
|---|---|
| Ticker | DMII |
| CIK | 0002040475 |
| Boerse | US |
| Sektor | Financial Services |
| Industrie | Shell Companies |
| SIC | 6770 · Blank Checks |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 525,4 Mio. USD |
| Beta | 0,11 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 4,187,050 | 504,959,837 | -17,774,827 | ||
| 2025-09-30 | 10-Q | -46,158 | 501,005,711 | -17,280,989 | ||
| 2025-06-30 | 10-Q | -38,073 | -214,119 | |||
| 2025-03-31 | 10-Q | -59,327 | -176,046 | |||
| 2024-12-31 | 10-K | -151,719 | 138,064 | -116,719 | ||
| 2024-09-30 | 10-Q | -41,684 | -6,684 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-09-26 | Stockwell Lynn | Director, Officer, 10% Owner, CEO and Exe. Chair of Board | Open Market Purchase | 700,000 | 0.00 | 0.00 | 0,0% | |
| 2025-09-26 | Stockwell Lynn | Director, Officer, 10% Owner, CEO and Exe. Chair of Board | Open Market Sale | -7,966,667 | 0.00 | 0.00 | 0,0% | |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | 10% Owner | Open Market Purchase | 700,000 | 0.00 | 0.00 | 0,0% | |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | 10% Owner | Open Market Sale | -7,966,667 | 0.00 | 0.00 | 0,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.